Taxol/cisplatin three-hour therapy causes higher rate of peripheral neuropathy -- Gynecologic Oncology.
Executive Summary
TAXOL/CISPLATIN THREE-HOUR COMBO THERAPY INCREASES PERIPHERAL NERVE DAMAGE incidence compared to the regimen given over 24 hours, according to results of a study published in the August issue of Gynecologic Oncology. The 38-patient study was conducted at the Cleveland Clinic Cancer Center in Ohio and involved 20 ovarian, six primary peritoneal and 12 endometrial malignancy patients who were administered 170 cycles of 135 mg/m2 or 175 mg/m2 paclitaxel (Bristol-Myers Squibb's Taxol) over three hours immediately followed by 75 mg/m2 cisplatin delivered over 30 minutes.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth